Cabaletta Bio, Inc. (CABA)

Cabaletta Bio's stock has experienced fluctuations, declining by 24.16% between January 7, 2025, and January 6, 2026. Key events include the Third Quarter 2025 Financial Results reporting a widened loss and a "going-concern risk", participation in investor conferences, presentation of positive clinical data for rese-cel at ACR Convergence 2025, Q2 loss widening but securing FDA alignment and raising approximately $94 million, participation in healthcare conferences, announcement of 2026 Strategic Priorities, a "Buy" rating from a William Blair analyst, and FDA orphan designation for its myasthenia gravis treatment.

Traditional demand seasonality is not applicable to Cabaletta Bio as its therapies are still in development. However, seasonal patterns in its stock performance suggest a "Buy Date of August 8 and a Sell Date of December 2," which has historically resulted in a geometric average return of 51.68% above the S&P 500. This seasonal timeframe aligns with the broader Healthcare sector's period of seasonal strength, typically from April 25 to December 4.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases. The company's CABA™ platform includes CARTA and CAART strategies, with its lead product candidate, rese-cel, in Phase 1/2 clinical trials. Rese-cel is being evaluated for various conditions, and the company is also developing DSG3-CAART and MuSK-CAART for specific autoimmune diseases.

Cabaletta Bio, Inc. is headquartered in Philadelphia, Pennsylvania, United States. The company collaborates with institutions such as the University of Pennsylvania and the Children's Hospital of Philadelphia, as well as with international partners including Nanjing IASO Biotherapeutics Co., Ltd, Oxford Biomedica, Autolus Holdings (UK) Limited, and WuXi Advanced Therapies, Inc.

Cabaletta Bio's brand reputation has been influenced by its clinical progress and financial performance. Positive clinical data and FDA agreement enhance its standing, while the widening of its Q3 2025 loss and the mention of a "going-concern risk" could have negatively impacted its financial reputation. Despite these financial challenges, the company has received a consensus "buy" rating from analysts.

Cabaletta Bio, Inc. is primarily owned by institutional investors, who hold approximately 71.90% to 72.77% of the company's stock. Insiders own around 1.62% to 4.39%, while retail investors account for roughly 23.72% to 25.61% of the ownership. Major institutional shareholders include Bain Capital Life Sciences Investors LLC, Adage Capital Partners GP LLC, Jennison Associates LLC, T. Rowe Price Investment Management, Inc., Cormorant Asset Management, LP, and Vanguard Group Inc. James E. Flynn is the largest individual shareholder.